Entrada Therapeutics Inc. (TRDA)
NASDAQ · Healthcare
Entrada Therapeutics Inc. Shareholder Equity 2023–2025
Entrada Therapeutics Inc. annual/quarterly shareholder equity history from 2023 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Entrada Therapeutics Inc. shareholder equity for the quarter ending December 31, 2025 were 306.1M, a 28.59% decrease year-over-year.
- Entrada Therapeutics Inc. shareholder equity for 2025 were 306.1M, a 28.59% decrease from 2024.
- Entrada Therapeutics Inc. shareholder equity for 2024 were 428.7M, a 76.88% increase from 2023.
- Entrada Therapeutics Inc. shareholder equity for 2023 were 242.4M.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| Entrada Therapeutics Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $306 |
| 2024 | $429 |
| 2023 | $242 |
| Entrada Therapeutics Inc. Quarterly Shareholder Equity (Millions of US $) | |
|---|---|
| 2025-12-31 | $306 |
| 2024-12-31 | $429 |
| 2023-12-31 | $242 |
Entrada Therapeutics Inc. Shareholder Equity — FAQ
Entrada Therapeutics Inc. (TRDA) shareholder equity over the last 3 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see TRDA's shareholder equity history?
The chart and table above show Entrada Therapeutics Inc.'s shareholder equity by year and by quarter, including the growth rate.